Annual CFF
$345.77 M
+$321.22 M+1308.44%
31 December 2023
Summary:
CymaBay Therapeutics annual cash flow from financing activities is currently $345.77 million, with the most recent change of +$321.22 million (+1308.44%) on 31 December 2023. During the last 3 years, it has risen by +$227.32 million (+191.90%).CBAY Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$2.73 M
-$246.19 M-98.90%
31 December 2023
Summary:
CymaBay Therapeutics quarterly cash flow from financing activities is currently $2.73 million, with the most recent change of -$246.19 million (-98.90%) on 31 December 2023.CBAY Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$345.77 M
+$2.73 M+0.80%
31 December 2023
Summary:
CymaBay Therapeutics TTM cash flow from financing activities is currently $345.77 million, with the most recent change of +$2.73 million (+0.80%) on 31 December 2023.CBAY TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CBAY Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +191.9% | -97.1% | +191.9% |
| 5 y5 years | +219.8% | +867.7% | +219.8% |
CBAY Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | at high | -98.9% | at high |
CymaBay Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $345.77 M(+1308.4%) | $2.73 M(-98.9%) | $345.77 M(+0.8%) |
| Sept 2023 | - | $248.92 M(>+9900.0%) | $343.04 M(+264.4%) |
| June 2023 | - | $1.05 M(-98.9%) | $94.13 M(+1.1%) |
| Mar 2023 | - | $93.07 M(>+9900.0%) | $93.08 M(+279.1%) |
| Dec 2022 | $24.55 M(-79.3%) | $0.00(-100.0%) | $24.55 M(-79.5%) |
| Sept 2022 | - | $9000.00(>+9900.0%) | $119.71 M(-16.2%) |
| June 2022 | - | $0.00(-100.0%) | $142.89 M(-0.1%) |
| Mar 2022 | - | $24.54 M(-74.2%) | $143.00 M(+20.7%) |
| Dec 2021 | $118.45 M(>+9900.0%) | $95.16 M(+310.4%) | $118.45 M(+406.7%) |
| Sept 2021 | - | $23.19 M(>+9900.0%) | $23.38 M(>+9900.0%) |
| June 2021 | - | $106.00 K(>+9900.0%) | $191.00 K(+107.6%) |
| Mar 2021 | - | $0.00(-100.0%) | $92.00 K(0.0%) |
| Dec 2020 | $92.00 K(-99.9%) | $85.00 K(>+9900.0%) | $92.00 K(-68.2%) |
| Sept 2020 | - | $0.00(-100.0%) | $289.00 K(0.0%) |
| June 2020 | - | $7000.00(>+9900.0%) | $289.00 K(+151.3%) |
| Mar 2020 | - | $0.00(-100.0%) | $115.00 K(-99.9%) |
| Dec 2019 | $108.13 M(-19.9%) | $282.00 K(>+9900.0%) | $108.13 M(+0.2%) |
| Sept 2019 | - | $0.00(-100.0%) | $107.87 M(-1.4%) |
| June 2019 | - | -$167.00 K(-100.2%) | $109.41 M(+4.8%) |
| Mar 2019 | - | $108.02 M(>+9900.0%) | $104.38 M(-22.7%) |
| Dec 2018 | $134.99 M | $24.00 K(-98.4%) | $134.99 M(-0.7%) |
| Sept 2018 | - | $1.54 M(-129.6%) | $135.98 M(-39.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | -$5.20 M(-103.7%) | $225.31 M(-1.9%) |
| Mar 2018 | - | $138.62 M(>+9900.0%) | $229.74 M(+130.4%) |
| Dec 2017 | $99.72 M(<-9900.0%) | $1.02 M(-98.9%) | $99.72 M(+1.8%) |
| Sept 2017 | - | $90.87 M(<-9900.0%) | $97.96 M(+1331.3%) |
| June 2017 | - | -$775.00 K(-109.0%) | $6.84 M(-10.2%) |
| Mar 2017 | - | $8.61 M(-1259.7%) | $7.62 M(-872.7%) |
| Dec 2016 | -$986.00 K(-103.2%) | -$742.00 K(+204.1%) | -$986.00 K(+304.1%) |
| Sept 2016 | - | -$244.00 K(<-9900.0%) | -$244.00 K(-100.9%) |
| June 2016 | - | $0.00(0.0%) | $26.60 M(+1.5%) |
| Mar 2016 | - | $0.00(0.0%) | $26.21 M(-14.1%) |
| Dec 2015 | $30.53 M(+21.0%) | $0.00(-100.0%) | $30.53 M(+0.6%) |
| Sept 2015 | - | $26.60 M(-7026.0%) | $30.33 M(+13.3%) |
| June 2015 | - | -$384.00 K(-108.9%) | $26.76 M(-1.4%) |
| Mar 2015 | - | $4.32 M(-2301.5%) | $27.15 M(+7.6%) |
| Dec 2014 | $25.24 M(-19.5%) | -$196.00 K(-100.9%) | $25.24 M(-9.8%) |
| Sept 2014 | - | $23.03 M(>+9900.0%) | $27.97 M(-17.2%) |
| June 2014 | - | $3000.00(-99.9%) | $33.77 M(+0.0%) |
| Mar 2014 | - | $2.40 M(-5.4%) | $33.77 M(+7.7%) |
| Dec 2013 | $31.36 M(<-9900.0%) | $2.54 M(-91.2%) | $31.36 M(+8.8%) |
| Sept 2013 | - | $28.82 M(>+9900.0%) | $28.82 M(>+9900.0%) |
| June 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | -$12.00 K | - | - |
FAQ
- What is CymaBay Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for CymaBay Therapeutics?
- What is CymaBay Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for CymaBay Therapeutics?
- What is CymaBay Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for CymaBay Therapeutics?
What is CymaBay Therapeutics annual cash flow from financing activities?
The current annual CFF of CBAY is $345.77 M
What is the all time high annual CFF for CymaBay Therapeutics?
CymaBay Therapeutics all-time high annual cash flow from financing activities is $345.77 M
What is CymaBay Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of CBAY is $2.73 M
What is the all time high quarterly CFF for CymaBay Therapeutics?
CymaBay Therapeutics all-time high quarterly cash flow from financing activities is $248.92 M
What is CymaBay Therapeutics TTM cash flow from financing activities?
The current TTM CFF of CBAY is $345.77 M
What is the all time high TTM CFF for CymaBay Therapeutics?
CymaBay Therapeutics all-time high TTM cash flow from financing activities is $345.77 M